Compare USAS & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USAS | INBX |
|---|---|---|
| Founded | 1998 | 2010 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2004 | 2024 |
| Metric | USAS | INBX |
|---|---|---|
| Price | $4.31 | $84.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | $6.50 | ★ $150.00 |
| AVG Volume (30 Days) | ★ 3.7M | 249.2K |
| Earning Date | 05-11-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,300,000.00 |
| Revenue This Year | $174.68 | N/A |
| Revenue Next Year | $53.17 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $0.87 | $20.55 |
| 52 Week High | $10.50 | $155.29 |
| Indicator | USAS | INBX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 44.34 |
| Support Level | N/A | $69.57 |
| Resistance Level | N/A | $85.97 |
| Average True Range (ATR) | 0.00 | 4.45 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 0.00 | 49.91 |
Americas Gold And Silver Corp is a mining company engaged in the acquisition, exploration, development, and production of precious metals mineral properties in Mexico and the United States. The company's primary operating assets, which are also its reporting segments, are the Cosala operations, the Galena Complex, and Relief Canyon. It also holds interests in the San Felipe Development Project located in Sonora, Mexico. The Cosala operations segment, which derives maximum revenue, operates in Mexico, while the Galena Complex and Relief Canyon segments operate in the United States.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.